回盛生物：公司高度重视技术创新

Core Viewpoint - The company emphasizes its commitment to innovation and collaboration in research and development, focusing on both the quantity and quality of its R&D efforts [2] Group 1: R&D Strategy - The company is enhancing its R&D foundation and optimizing conventional drug processes to improve cost-effectiveness [2] - It is accelerating the transformation of R&D results, particularly in the fields of biological veterinary medicine and traditional Chinese veterinary medicine [2] Group 2: New Product Development - The company has obtained approval for six new veterinary drug formulations this year, including two products, chlorhexidine acetate soft capsules and enconazole solution, which fill gaps in the domestic market [2] - The approval of new products is expected to enhance the company's market competitiveness, although market acceptance for these new products will require time [2]